Why did Marker Therapeutics issue an 8-K related to its 2026 Annual Meeting?

Marker Therapeutics filed this 8-K because its 2026 meeting date is advanced by more than 30 days versus 2025. Under Rule 14a-18 , the company must inform shareholders of the new meeting date and the adjusted deadline for submitting proposals.

Marker Therapeutics (MRKR) moves 2026 annual meeting, sets March 9 proxy proposal cutoff

Q: Where must MRKR shareholders send proposals or director nominations for the 2026 Annual Meeting?

Shareholders must deliver proposals or nominations to Marker Therapeutics, Inc., Attn: Corporate Secretary, 2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, Texas 77021 . Using the precise address helps ensure timely and proper receipt by the company.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Marker Therapeutics, Inc. has set the date for its 2026 Annual Meeting of Stockholders for May 1, 2026. This meeting date is more than 30 days earlier than the prior year’s annual meeting, which triggers updated notice requirements for shareholder proposals.

The company states that stockholder proposals intended for inclusion in the 2026 proxy statement under SEC Rule 14a-8 must be received at its Houston headquarters by March 9, 2026. The specific record date, time, and location of the meeting will be provided in the upcoming proxy statement.

8-K Event Classification

2 items: 5.08, 9.01

2 items

Item 5.08 Shareholder Director Nominations Governance

Shareholder nominations for board of directors under proxy access rules. Rarely used -- the underlying SEC rule was vacated.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

02/09/2026 - 04:06 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

February 9, 2026

Date of Report (Date of earliest event reported)

MARKER THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware	001-37939	45-4497941
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

2450 Holcombe Blvd, TMC Partners Office 1.311

Houston, Texas

77021

(Address of principal executive offices)

(Zip Code)

(713) 400-6400

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		MRKR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 5.08 Shareholder Director Nominations

On February 9, 2026, the Board of Directors of Marker Therapeutics, Inc. (the “Company”) determined it is in the best interest of the Company to schedule Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) for May 1, 2026. Because the date of the 2026 Annual Meeting has advanced by more than 30 days from the anniversary date of the Company’s 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”), in accordance with Rule 14a−18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company is informing stockholders of such change and that, accordingly, a new deadline has been set for submission of proposals by Stockholders intended to be included in the Company’s 2026 proxy statement and form of proxy. Proposals to be included in the Company’s proxy statement for the 2026 Annual Meeting in accordance with Rule 14a-8 under the Exchange Act must be received by the Company on or before March 9, 2026, which the Company believes is a reasonable time before it expects to begin to print and send its proxy materials. Stockholders must deliver the proposals or nominations to the Company’s principal executive offices at the following address: Marker Therapeutics, Inc., Attn: Corporate Secretary, 2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, Texas 77021. The record date, time and location of the 2026 Annual Meeting will be as set forth in the Company’s proxy statement for the 2026 Annual Meeting.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description

104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Marker Therapeutics, Inc.

Dated: February 9, 2026	By:	/s/ Juan Vera
		Juan Vera
		President and Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

When is Marker Therapeutics (MRKR) holding its 2026 Annual Meeting of Stockholders?

Marker Therapeutics plans to hold its 2026 Annual Meeting of Stockholders on May 1, 2026. This date is more than 30 days earlier than the prior year’s meeting, prompting revised shareholder proposal deadlines under SEC rules.

What is the deadline for MRKR shareholders to submit proposals for the 2026 proxy statement?

Shareholder proposals for inclusion in Marker Therapeutics’ 2026 proxy statement under Rule 14a-8 must be received by March 9, 2026. Proposals received after that date may not be included in the company’s proxy materials for the meeting.

Where must MRKR shareholders send proposals or director nominations for the 2026 Annual Meeting?

Shareholders must deliver proposals or nominations to Marker Therapeutics, Inc., Attn: Corporate Secretary, 2450 Holcombe Blvd, TMC Partners Office 1.311, Houston, Texas 77021. Using the precise address helps ensure timely and proper receipt by the company.

Will the record date and exact location for MRKR’s 2026 Annual Meeting be disclosed now?

The record date, time, and specific location for Marker Therapeutics’ 2026 Annual Meeting will be detailed in the forthcoming proxy statement. This filing only sets the meeting date and shareholder proposal deadline, with further logistical information to follow.

Filing Exhibits & Attachments

3 documents